Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-2325a in healthy subjects
NCT05388903Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Gene Silencing, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DS-2325a in Netherton syndrome (NS) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Number of Participants with Any Treatment-emergent Adverse Events. Started Jun 2022; status: completed.
02
Drugs
DS-2325a
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NCT05388903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388903.